732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial
| Autor: | Champiat, S., Wermke, M., Vicier, C., de Bono, J.S., Jungels, C., Vey, N., Kotecki, N., Wetzko, K., Ruhnke, L., Garralda, E., Galvao de Aguiar, V., Lorusso, P., de Gassart, A., Valentin, E., Brune, P., Iche, M., Leparquier, C., Olive, D., Marabelle, A., Frohna, P.A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S877-S878 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|